Gb Sciences, Inc. (OTCQB:GBLX)

Gb Sciences, Inc. (OTCQB:GBLX) is a plant-based research and biopharmaceutical drug development company. Our goal is to create patented formulations of plant-inspired, minimum essential mixtures for the prescription drug market to treat a variety of conditions.

Gb Sciences’ novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 19 US and 40 international patent-pending applications. In our drug development pipeline, we have four preclinical stage programs, and our lead Parkinson’s disease therapeutic program is being prepared for a First-in-Man clinical trial.

Upcoming Events

Gb Sciences presenting at Cannabis Conference August 24, 2021
Gb Sciences presenting at HC WainWright & Co. September 8, 2021
Gb Sciences presenting at SNN Network August 18, 2021

Most Recent Investor Presentation

Gb Sciences’ Drug Development Programs

Letter to Shareholder's

GBLX Stock Price

The GBLX stock price will be updated periodically, but there may be a lag with respect to real-time stock quotes

SEC Filings for Gb Sciences, Inc.

Latest News from Gb Sciences

Gb Sciences’ Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

Gary Herman Joins GB Sciences’ Subsidiary GbS Global Biopharma as Advisory Director

Media Contact

Alexis Quintal

alexis@newswire.com